STOCK TITAN

Medigus Ltd. American Depositary Share - MDGS STOCK NEWS

Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.

Medigus Ltd. (NASDAQ: MDGS) is an innovative medical device company renowned for its groundbreaking endoscopic procedures and devices. The company has developed a comprehensive endoscopic system designed for the intraluminal treatment of Gastroesophageal Reflux Disease (GERD), a prevalent chronic condition in the Western world. The centerpiece of Medigus's offering is the SRS system, which integrates a miniaturized video camera, surgical stapler, and ultrasonic sights for precise alignment into a single, flexible endoscope. This unique system allows gastroenterologists and surgeons to perform endoluminal partial anterior fundoplications, thereby eliminating the need for traditional open or laparoscopic surgery, significantly advancing the clinical management of GERD.

Alongside its flagship SRS system, Medigus also designs and manufactures bespoke endoscopy systems for partner companies, leveraging its proprietary technology to meet diverse clinical needs. This dual focus on innovation in GERD treatment and custom endoscopic solutions underscores Medigus's commitment to advancing medical care through minimally invasive techniques.

Based in Israel, Medigus's recent initiatives include strategic partnerships and collaborations to expand the reach and application of their technologies. The company's financial health is bolstered by these partnerships, alongside a strong pipeline of ongoing projects aimed at enhancing patient outcomes and broadening the scope of endoscopic treatments.

For the latest updates, news, and detailed financial information, stakeholders can contact: Tali Dinar, Chief Financial Officer, at ir@medigus.com, or Michal Efraty, Investor Relations, at michal@efraty.com.

Rhea-AI Summary
Medigus (NASDAQ: MDGS) announced a corporate rebranding to Xylo Technologies with a new trading symbol XYLO on April 18, 2024. The rebranding signifies the Company's focus on innovation technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
Rhea-AI Summary
Medigus announces a milestone achievement by its subsidiary, Charging Robotics , in successfully installing a wireless charging system for an automatic parking system, a first in the industry. The system, reaching a power of 10kW, aims to address the challenge of charging electric vehicles in automatic car parks by utilizing wireless technology. The innovative solution allows for efficient charging without the need for manual cable connections, enhancing the convenience for EV owners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary
Medigus (Nasdaq: MDGS) announces the completion of the initial production batch of 50 units of its micro-mobility electric vehicle 'PORTO' by its EV joint venture Revoltz The joint venture aims to sell 150 vehicles in the first year under a $2.7 million revenue Agreement with a premier distributor in Israel. The PORTO EV offers a 100 km range, 250L delivery payload, and advanced stability features, tailored for the last-mile delivery market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.1%
Tags
none
Rhea-AI Summary
Medigus (Nasdaq: MDGS) subsidiary, Charging Robotics , successfully installs wireless charging system for automatic car parks in Tel Aviv, Israel. The system reaches a charging power of 10kW, includes managed charging capabilities, and a user interface on the driver's smartphone. This innovative solution aims to address the challenge of charging electric vehicles parked in automatic car parks, where traditional cables are impractical. Charging Robotics collaborated with Make My Day for the system's user interface.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announces the expansion of collaboration between ParaZero Technologies Ltd. and Vayu Aerospace Corporation to integrate safety systems into Vayu's fleet of delivery drones. The global VTOL unmanned aerial vehicles market is projected to reach $27.5 Billion by 2030, with a CAGR of 19.9% between 2022 and 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
partnership
-
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announces the pre-order launch of PORTO, an innovative electric vehicle (EV) from its subsidiary, Revoltz Ltd. The pre-order launch is led by Revoltz Ltd., a company specializing in high-end, mini electric vehicles, bringing innovation and elevating single-rider transportation. The PORTO is designed for modern cities, combining long-range capability, robust design, and exceptional agility, marking a significant step in Revoltz's commitment to sustainable, efficient, and cutting-edge urban logistics solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.57%
Tags
none
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced that its subsidiary, Charging Robotics Ltd., has successfully completed an important milestone towards the installation of its wireless charging system in automatic car parks as part of its pilot program with an automatic car park provider in Israel. The successful experiment for transferring high voltage electricity wirelessly needed for EV charging will enable the pilot program to progress to the next step, which is the full charging of an EV using the wireless charging system developed by Charging Robotics at a higher voltage. The global Automated Parking System market was valued at USD 1.8 billion in 2022 and is expected to grow to USD 5.2 billion by 2032, with an estimated CAGR of 11.4% between 2023 and 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced the launch of a unique pilot of a wireless charging solution for electric vehicles in automated parking systems. The project was led by Charging Robotics Ltd., a subsidiary of Fuel Doctor Holdings, Inc., and received funding from the Israel Innovation Authority. The global Automated Parking System market is expected to grow to USD 5.2 billion by 2032, creating potential for a more sustainable and efficient future for transportation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.05%
Tags
none
-
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) subsidiary ParaZero Technologies Ltd. (PRZO) has successfully completed the development of a custom variant of its SafeAirâ„¢ drone safety system for a Fortune 500 automotive manufacturer, reinforcing its position as a leader in the aerospace industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
none
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announced that Jeffs' Brands Ltd. will hold a 70% interest in a new company to develop laser-based charging solutions for drones and unmanned aircraft. The investment is worth $2.5 million, and the new technology aims to revolutionize wireless charging for drones and unmanned aircraft, making the process more efficient and convenient.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none

FAQ

What is the current stock price of Medigus Ltd. American Depositary Share (MDGS)?

The current stock price of Medigus Ltd. American Depositary Share (MDGS) is $2.36 as of June 11, 2024.

What is the market cap of Medigus Ltd. American Depositary Share (MDGS)?

The market cap of Medigus Ltd. American Depositary Share (MDGS) is approximately 4.5M.

What does Medigus Ltd. specialize in?

Medigus Ltd. specializes in innovative endoscopic procedures and devices, particularly for the treatment of GERD.

What is the SRS system?

The SRS system is an endoscopic solution that combines a miniaturized camera, surgical stapler, and ultrasonic sights to treat GERD without open or laparoscopic surgery.

How does the SRS system benefit GERD patients?

The SRS system allows for a minimally invasive procedure, reducing the need for more invasive surgeries and potentially improving recovery times.

Does Medigus Ltd. collaborate with other companies?

Yes, Medigus designs and manufactures endoscopy systems for partner companies using its proprietary technologies.

Where is Medigus Ltd. based?

Medigus Ltd. is based in Israel.

Who can I contact for investor relations at Medigus?

For investor relations, you can contact Michal Efraty at michal@efraty.com.

What is the primary medical condition that Medigus's technology addresses?

Medigus's technology primarily addresses Gastroesophageal Reflux Disease (GERD).

How does the SRS system work?

The SRS system uses a flexible endoscope with a built-in camera, stapler, and ultrasonic guide to perform partial anterior fundoplication endoluminally.

What are the recent initiatives of Medigus Ltd.?

Recent initiatives include strategic partnerships and ongoing projects to enhance their technology's reach and applications.

How can I get the latest news about Medigus Ltd.?

You can get the latest news by contacting their Chief Financial Officer Tali Dinar or Investor Relations Michal Efraty, or visiting their official communications.

Medigus Ltd. American Depositary Share

Nasdaq:MDGS

MDGS Rankings

MDGS Stock Data

4.47M
28.42M
0.29%
0.22%
Medical Devices
Healthcare
Link
United States of America
Tel Aviv